{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:24:52Z","timestamp":1787898292966,"version":"build-2784847793"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Toronto Western Hospital, Neurosurgery Department"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Aggressive pituitary tumors and pituitary Carcinomas (PCs) represent very uncommon entities within the field of pituitary diseases. Unfortunately, treatment options after progression on temozolomide are limited. However, advances in the understanding of pituitary tumor genetics and their immunological landscape are paving the way for new targeted molecular therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this article, we present an overview of the most recent literature, focusing on the specificities and role of current treatments and future perspectives in the management of these lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and Conclusions<\/jats:title>\n                  <jats:p>Aggressive pituitary tumors and PCs remain very challenging conditions requiring a specific multidisciplinary approach in Pituitary Tumor Centers of excellence. If standard therapy fails, Temozolomide represents the first-line treatment option. Peptide Receptor Radionuclide Therapy may be also considered, especially in tumors expressing specific Somatostatin receptors. When tumors progress after Temozolomide treatment, the prognosis is typically poor, and among the various second-line treatment options immune checkpoint inhibitors have proven to be the most effective. Further studies exploring new potential targeted therapies and predictive factors for pituitary tumor aggressiveness are now essential to improve the management and outcomes for these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae114","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T12:16:53Z","timestamp":1735820213000},"page":"i17-i28","source":"Crossref","is-referenced-by-count":4,"title":["Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice"],"prefix":"10.1093","volume":"7","author":[{"given":"Francesco","family":"Calvanese","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Helsinki University Central Hospital, Helsinki University , Helsinki ,","place":["Finland"]},{"name":"Skull Base and Pituitary Unit, Department of Neurosurgery B, Neurological Hospital Pierre-Wertheimer , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Jannelli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Neurocenter of Southern Switzerland , EOC, Lugano ,","place":["Switzerland"]},{"name":"Skull Base and Pituitary Unit, Department of Neurosurgery B, Neurological Hospital Pierre-Wertheimer , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Feuvret","sequence":"additional","affiliation":[{"name":"Radiation oncology Department, \u201cGroupement Hospitalier Est,\u201d Hospices Civils de Lyon , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Cancer Research Center of Lyon, University Claude-Bernard Lyon 1 , Lyon ,","place":["France"]},{"name":"Lyon 1 University , Villeurbanne ,","place":["France"]},{"name":"Histological Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est,\u201d Hospices civils de Lyon, \u201cClaude-Bernard\u201d Lyon 1 University, H\u00f4pital Louis-Pradel , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Manet","sequence":"additional","affiliation":[{"name":"Skull Base and Pituitary Unit, Department of Neurosurgery B, Neurological Hospital Pierre-Wertheimer , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Sergeant","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est,\u201d Hospices civils de Lyon, \u201cClaude-Bernard\u201d Lyon 1 University, H\u00f4pital Louis-Pradel , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est,\u201d Hospices civils de Lyon, \u201cClaude-Bernard\u201d Lyon 1 University, H\u00f4pital Louis-Pradel , Lyon ,","place":["France"]},{"name":"Inserm U1052, CNRS UMR5286, Cancer Research Center of Lyon, University Claude-Bernard Lyon 1 , Lyon ,","place":["France"]},{"name":"Lyon 1 University , Villeurbanne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est,\u201d Hospices civils de Lyon, \u201cClaude-Bernard\u201d Lyon 1 University, H\u00f4pital Louis-Pradel , Lyon ,","place":["France"]},{"name":"Inserm U1052, CNRS UMR5286, Cancer Research Center of Lyon, University Claude-Bernard Lyon 1 , Lyon ,","place":["France"]},{"name":"Skull Base and Pituitary Unit, Department of Neurosurgery B, Neurological Hospital Pierre-Wertheimer , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"6","key":"2025072409165896600_CIT0001","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev."},{"key":"2025072409165896600_CIT0002","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025072409165896600_CIT0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11102-021-01189-6","article-title":"Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification","volume":"25","author":"Castellanos","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2025072409165896600_CIT0004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11102-018-0912-4","article-title":"Correction to: Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A pituitary society statement","volume":"21","author":"Casanueva","year":"2018","journal-title":"Pituitary"},{"issue":"1","key":"2025072409165896600_CIT0005","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2025072409165896600_CIT0006","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2025072409165896600_CIT0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","article-title":"Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification","volume":"19","author":"Ho","year":"2023","journal-title":"Nat Rev Endocrinol."},{"issue":"8","key":"2025072409165896600_CIT0008","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"2","key":"2025072409165896600_CIT0009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2025072409165896600_CIT0010","doi-asserted-by":"crossref","first-page":"101712","DOI":"10.1016\/j.beem.2022.101712","article-title":"Immunotherapy in pituitary carcinomas and aggressive pituitary tumors","volume":"36","author":"Raverot","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"5","key":"2025072409165896600_CIT0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11102-023-01348-x","article-title":"Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input","volume":"26","author":"Jouanneau","year":"2023","journal-title":"Pituitary"},{"issue":"2","key":"2025072409165896600_CIT0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","article-title":"Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician\u2019s questions","volume":"21","author":"Trouillas","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"2","key":"2025072409165896600_CIT0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40618-018-0901-5","article-title":"Advances and controversies in the classification and grading of pituitary tumors","volume":"42","author":"Laws","year":"2019","journal-title":"J Endocrinol Invest."},{"key":"2025072409165896600_CIT0014","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jocn.2021.06.010","article-title":"Assessment of magnetic resonance imaging criteria for the diagnosis of cavernous sinus invasion by pituitary tumors","volume":"90","author":"Chang","year":"2021","journal-title":"J Clin Neurosci."},{"issue":"1","key":"2025072409165896600_CIT0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","journal-title":"Cancer."},{"issue":"3","key":"2025072409165896600_CIT0016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2025072409165896600_CIT0017","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2025072409165896600_CIT0018","doi-asserted-by":"crossref","first-page":"C5","DOI":"10.1093\/ejendo\/lvad042","article-title":"Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question","volume":"188","author":"Trouillas","year":"2023","journal-title":"Eur J Endocrinol."},{"issue":"9","key":"2025072409165896600_CIT0019","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/js.2019-00130","article-title":"Comparison of radiographic approaches to assess treatment response in pituitary adenomas: Is RECIST or RANO Good Enough","volume":"3","author":"Imber","year":"2019","journal-title":"J Endocr Soc."},{"issue":"2","key":"2025072409165896600_CIT0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"3","key":"2025072409165896600_CIT0021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","article-title":"Aggressive pituitary adenomas and carcinomas","volume":"49","author":"Ilie","year":"2020","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"11","key":"2025072409165896600_CIT0022","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00701-021-04953-6","article-title":"Aggressive pituitary neuroendocrine tumors: Current practices, controversies, and perspectives, on behalf of the EANS skull base section","volume":"163","author":"Ng","year":"2021","journal-title":"Acta Neurochir (Wien)."},{"issue":"7","key":"2025072409165896600_CIT0023","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: From pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2025072409165896600_CIT0024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1530\/EJE-22-0812","article-title":"Real-life clinical impact of a five-tiered classification of pituitary tumors","volume":"187","author":"Sahakian","year":"2022","journal-title":"Eur J Endocrinol."},{"key":"2025072409165896600_CIT0025","doi-asserted-by":"crossref","first-page":"102920","DOI":"10.1016\/j.arcmed.2023.102920","article-title":"Genetic testing in hereditary pituitary tumors","volume":"54","author":"Akku\u015f","year":"2023","journal-title":"Arch Med Res."},{"issue":"3","key":"2025072409165896600_CIT0026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: More macrophages in larger adenomas and more t cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr Pathol."},{"issue":"3","key":"2025072409165896600_CIT0027","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2025072409165896600_CIT0028","doi-asserted-by":"crossref","first-page":"dgaa520","DOI":"10.1210\/clinem\/dgaa520","article-title":"Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion","volume":"105","author":"Principe","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2025072409165896600_CIT0029","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2025072409165896600_CIT0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11102-019-01000-7","article-title":"Aggressive prolactinomas: How to manage","volume":"23","author":"Lasolle","year":"2020","journal-title":"Pituitary"},{"issue":"8","key":"2025072409165896600_CIT0031","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: An endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2025072409165896600_CIT0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-term survival after transformation of an adrenocorticotropic hormone-secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurg"},{"issue":"9\u201310","key":"2025072409165896600_CIT0033","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000506902","article-title":"Radiotherapy of parasellar tumours","volume":"110","author":"Albano","year":"2020","journal-title":"Neuroendocrinology."},{"issue":"2","key":"2025072409165896600_CIT0034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11154-020-09543-y","article-title":"Radiation techniques in aggressive pituitary tumours and carcinomas","volume":"21","author":"Castinetti","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"4","key":"2025072409165896600_CIT0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11154-020-09564-7","article-title":"The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective","volume":"21","author":"Mortini","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"key":"2025072409165896600_CIT0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-013-1262-8","article-title":"Treatment paradigms for pituitary adenomas: Defining the roles of radiosurgery and radiation therapy","volume":"117","author":"Ding","year":"2014","journal-title":"J Neurooncol."},{"key":"2025072409165896600_CIT0037","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1016\/j.wneu.2019.05.066","article-title":"Adjuvant radiation therapy compared with observation alone for postoperative residual nonfunctional pituitary adenomas","volume":"128","author":"Deng","year":"2019","journal-title":"World Neurosurgery"},{"issue":"6","key":"2025072409165896600_CIT0038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11102-013-0541-x","article-title":"Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas","volume":"17","author":"Verma","year":"2014","journal-title":"Pituitary"},{"issue":"4","key":"2025072409165896600_CIT0039","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11102-016-0721-6","article-title":"Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma","volume":"19","author":"Kamiya-Matsuoka","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"2025072409165896600_CIT0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-020-03579-5","article-title":"Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas","volume":"149","author":"Minniti","year":"2020","journal-title":"J Neurooncol."},{"issue":"3","key":"2025072409165896600_CIT0041","doi-asserted-by":"crossref","first-page":"dgz211","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a German survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2025072409165896600_CIT0042","first-page":"188","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: Systematic review of case reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol. Pract.."},{"issue":"10","key":"2025072409165896600_CIT0043","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"2025072409165896600_CIT0044","doi-asserted-by":"crossref","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: A systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol."},{"issue":"4","key":"2025072409165896600_CIT0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11102-009-0211-1","article-title":"Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor","volume":"14","author":"Thearle","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"2025072409165896600_CIT0046","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-course temozolomide in aggressive pituitary adenoma: Real-life experience in two tertiary care centers and review of the literature","volume":"23","author":"Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"2025072409165896600_CIT0047","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.3390\/cancers13184573","article-title":"Immune checkpoints in cancers: From signaling to the clinic","volume":"13","author":"Pisibon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025072409165896600_CIT0048","doi-asserted-by":"crossref","first-page":"108506","DOI":"10.1016\/j.pharmthera.2023.108506","article-title":"Therapeutic targeting of the pituitary tumor microenvironment","volume":"250","author":"Ilie","year":"2023","journal-title":"Pharmacol Ther."},{"issue":"7","key":"2025072409165896600_CIT0049","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: A systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2025072409165896600_CIT0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: A cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2025072409165896600_CIT0051","doi-asserted-by":"crossref","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocr Soc."},{"issue":"4","key":"2025072409165896600_CIT0052","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.14645","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","volume":"98","author":"Goichot","year":"2023","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2025072409165896600_CIT0053","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anticancer Drugs."},{"key":"2025072409165896600_CIT0054","doi-asserted-by":"crossref","first-page":"579599","DOI":"10.3389\/fonc.2020.579599","article-title":"A Review of Clinicopathological and molecular aspects","volume":"10","author":"Huntoon","year":"2020","journal-title":"Front Oncol."},{"issue":"10","key":"2025072409165896600_CIT0055","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-Secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2025072409165896600_CIT0056","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"issue":"1","key":"2025072409165896600_CIT0057","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: A new emerging treatment","volume":"184","author":"Sol","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2025072409165896600_CIT0058","doi-asserted-by":"crossref","first-page":"e001532","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: Report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"2","key":"2025072409165896600_CIT0059","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: A case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery."},{"key":"2025072409165896600_CIT0060","doi-asserted-by":"crossref","first-page":"576027","DOI":"10.3389\/fendo.2020.576027","article-title":"Case Report: A case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"2025072409165896600_CIT0061","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3390\/cancers14174093","article-title":"Immunotherapy for aggressive and metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art","volume":"14","author":"Feola","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2025072409165896600_CIT0062","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation\u2012positive child","volume":"104","author":"Dutta","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2025072409165896600_CIT0063","doi-asserted-by":"crossref","first-page":"e13022","DOI":"10.1200\/jco.2013.31.15_suppl.e13022","article-title":"Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: A case report","volume":"31","author":"O\u2019Riordan","year":"2013","journal-title":"J Clin Oncol."},{"issue":"03","key":"2025072409165896600_CIT0064","first-page":"178","article-title":"Bevacizumab in aggressive pituitary adenomas \u2013 experience with 3 patients","volume":"129","author":"Osterhage","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"2","key":"2025072409165896600_CIT0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An Institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol."},{"issue":"2","key":"2025072409165896600_CIT0066","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5306\/wjco.v11.i2.91","article-title":"Pituitary carcinoma: Two case reports and review of literature","volume":"11","author":"Xu","year":"2020","journal-title":"World J Clin Oncol."},{"issue":"3","key":"2025072409165896600_CIT0067","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF therapy in pituitary carcinoma","volume":"15","author":"Ortiz","year":"2012","journal-title":"Pituitary."},{"key":"2025072409165896600_CIT0068","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: A new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025072409165896600_CIT0069","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/brainsci13030515","article-title":"Current advances in papillary craniopharyngioma: State-of-the-art therapies and overview of the literature","volume":"13","author":"Jannelli","year":"2023","journal-title":"Brain Sci"},{"issue":"4","key":"2025072409165896600_CIT0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MED.0000000000000344","article-title":"Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: From bench to bedside","volume":"24","author":"Ben-Shlomo","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"2","key":"2025072409165896600_CIT0071","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2025072409165896600_CIT0072","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/jcm8081107","article-title":"Emerging and novel treatments for pituitary tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"2025072409165896600_CIT0073","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2018.2.FOCUS17660","article-title":"Regression of a nonfunctioning pituitary macroadenoma on the CDK4\/6 inhibitor palbociclib: Case report","volume":"44","author":"Anderson","year":"2018","journal-title":"Neurosurg Focus."},{"issue":"12","key":"2025072409165896600_CIT0074","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/clinem\/dgac574","article-title":"Peptide receptor radionuclide therapy","volume":"107","author":"Hofland","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2025072409165896600_CIT0075","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.3390\/cancers15102710","article-title":"The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary","volume":"15","author":"Marques","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025072409165896600_CIT0076","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: A monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect."},{"issue":"2","key":"2025072409165896600_CIT0077","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11154-020-09554-9","article-title":"Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas","volume":"21","author":"Petersenn","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"4","key":"2025072409165896600_CIT0078","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-14-0630","article-title":"GEP-NETS update: Interventional radiology: Role in the treatment of liver metastases from GEP-NETs","volume":"172","author":"de Baere","year":"2015","journal-title":"Eur J Endocrinol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae114\/61318567\/vdae114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_1\/i17\/61318567\/vdae114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_1\/i17\/61318567\/vdae114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:17:11Z","timestamp":1753363031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/7\/Supplement_1\/i17\/7941437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":78,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae114","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,1,2]]}}}